7 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
New approaches in the development of Hypoallergenic implant material in Orthopaedics: steps to personalised medicine (HYPORTH)
Date du début: 1 août 2013, Date de fin: 31 juil. 2018,
Europe is confronted by a demographic challenge as a decreasing work force has to support an increasing elderly population. The economic risk implied by this burden could be addressed by efforts to achieve an increase in Healthy Life Years. One key element would be to ensure unrestricted mobility for especially the elderly, allowing them to stay at work for longer. Irreversible joint deterioration ...
Voir le projet
11
Participants partenaires
TERMINÉ
Best EScalation Treatment in Multiple Sclerosis (MS) (BEST MS)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,
"Multiple Sclerosis (MS) is a devastating disease of the central nervous system affecting 2.5 million worldwide. MS is a field of constant therapeutic innovation, a fact which brings hope to young adults since MS is one of the most frequent causes of severe handicap. A major unmet need is to rationalize treatment decisions. To date, there is no way of predicting which patients will best respond to ...
Voir le projet
5
Participants partenaires
TERMINÉ
Identifying correlates of protection to accelerate vaccine trials: systems evaluation of two models of experimentally-induced immunity to malaria (SysMalVac)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2014,
Vaccine development is an empirical process (trial and error) and involves a long, expensive clinical development pipeline to license an efficacious vaccine candidate. Better tools for vaccine evaluation are needed to adapt to a rising number of candidate vaccines entering clinical trials for many diseases. Surrogate biomarkers of immunity offer the possibility of expediting the clinical developme ...
Voir le projet
8
Participants partenaires
TERMINÉ
Genes And Proteins for AutoImmunity Diagnostics (GAPAID)
Date du début: 1 sept. 2012, Date de fin: 31 août 2014,
"Rheumatoid arthritis (RA) and sistemic lupus erythematosus (SLE) are two autoimmune diseases that respectively affect an estimated population of 1.537.000 and 1.272.000 of patients in Europe. Such diseases show a long prodrome during which there are no clinical symptoms. In some cases, therapeutic treatments have been developed to improve patients quality of life. Therefore, reliable diagnostic/p ...
Voir le projet
10
Participants partenaires
TERMINÉ
NANOTECHNOLOGICAL TOOLKITS FOR MULTI-MODAL DISEASE DIAGNOSTICS AND TREATMENT MONITORING (NAMDIATREAM)
Date du début: 1 juil. 2010, Date de fin: 30 juin 2014,
NAMDIATREAM will develop a cutting edge nanotechnology-based toolkit for multi-modal detection of biomarkers of most common cancer types and cancer metastases, permitting identification of cells indicative of early disease onset in a high-specificity and throughput format in clinical, laboratory and point-of-care devices. The project is built on the innovative concepts of super-sensitive and highl ...
Voir le projet
24
Participants partenaires
TERMINÉ
United Europeans for the Development of Pharmacogenomics in Multiple Sclerosis (UEPHA-MS)
Date du début: 15 sept. 2008, Date de fin: 14 sept. 2012,
"Multiple sclerosis (MS) is a chronic inflammatory, disabling disease of the central nervous system. Recent studies suggest that over the last 50 years a disproportional increase in incidence of MS in women has taken place. The lifetime costs of MS exceed 1.5 million € per case in the UK, and are likely to be similar in other European countries. There is no definitive cure for MS. Immunomodulatory ...
Voir le projet
12
Participants partenaires
TERMINÉ
Mucosal protease and their inhibitors in inflammatory bowel disease: From etiopathogenetic insight to innovative therapy (IBDase)
Date du début: 1 mars 2008, Date de fin: 31 mai 2011,
IBDase addresses the etiology and pathogenesis of inflammatory bowel disease (IBD) with a multidisciplinary plan for innovative diagnosis and therapy focused on mucosal proteases and their inhibitors (P/PIs). The incidence of IBD, a multifactorial disease influenced by environmental factors in a background of complex genetic susceptibility, is rising, particularly among European children. Current ...
Voir le projet